In some patients, we could also exclusively detect mutations in melanoma driver genes (BRAF, NRAS, MAP2K1, KIT) suggesting that CTC analysis could complement ctDNA analysis for relevant clinical implications in personalized medicine in oncology. This evidence concerns the gene BRAF and melanoma.